All In MedTech

Device Trial Radar · NCT07911696

Comparative Effectiveness and Safety of Two Hyaluronic Acid Products in Knee Osteoarthritis

Comparative Evaluation of the Clinical Effectiveness, Safety, and Cost-Effectiveness of Two Hyaluronic Acid Products for Viscosupplementation in Patients With Knee Osteoarthritis: Real-World Evidence

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Coordinación de Investigación en Salud, MexicoGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Ortopedia Ana S.A. de C.V.
First posted
Nov 3, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Knee osteoarthritis is a condition that causes pain, stiffness, and difficulty moving the knee. Some people continue to have symptoms despite receiving usual treatments, such as pain medications, exercise, and physical therapy. One treatment option is viscosupplementation, which involves injecting a gel-like substance called hyaluronic acid into the knee joint. Different products are available, but it is not clear whether they provide similar benefits, have similar side effects, or differ in cost. The goal of this study is to compare two hyaluronic acid products, Mesoheal and Synvisc, in adults with knee osteoarthritis. The researchers want to find out: * How well each product reduces knee pain. * How much each product improves knee movement and daily activities. * What side effects may occur. * How the costs of the two treatments compare with their benefits. The study will include approximately 160 adults who need viscosupplementation as part of their usual medical care. Each person's doctor will choose the treatment based on their medical needs and routine clinical practice. The researchers will not assign treatments. Participants will be followed for six months. During this time, researchers will assess changes in pain, knee function, and any side effects that may occur. The results may help doctors and healthcare providers better understand the benefits, safety, and costs of these treatments in routine clinical care.

Conditions

  • Osteoarthritis, Knee

Interventions

  • Hylan G-F 20Device

    Hylan G-F 20 (Synvisc) is a sterile, cross-linked hyaluronan preparation of avian origin supplied in prefilled 2 mL syringes at a concentration of 8 mg/mL. It is administered by intra-articular injection into the knee according to the approved product instructions and routine clinical practice. Treatment selection and administration are determined by the treating physician independently of the research protocol.

  • Cross-Linked Sodium HyaluronateDevice

    Mesoheal is a sterile, non-animal-derived, cross-linked sodium hyaluronate preparation supplied in a prefilled 2.5 mL syringe containing 25 mg of sodium hyaluronate. It is administered by intra-articular injection into the knee according to the product instructions and routine clinical practice. Treatment selection and administration are determined by the treating physician independently of the research protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving Treatment Response at 6 MonthsTime frame: Baseline to 6 months after viscosupplementation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital de Ortopedia, UMAE "Dr. Victorio de la Fuente Narváez", IMSS

    Mexico City, Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.